El papel de los anti-inflamatorios no esteroideos en la producción de fasceítis necrotizante

Autores/as

  • Bertrand Behm López Caja Costarricense del Seguro Social, Centro Nacional de Control Dolor y Cuidados Paliativos
  • Isaías Salas Herrera Caja Costarricense del Seguro Social, Centro Nacional de Control Dolor y Cuidados Paliativos

DOI:

https://doi.org/10.51481/amc.v44i1.392

Palabras clave:

fasceítis necrotizante, anti-inflamatorios no esteroideos, infección, inmunosupresión

Resumen

Resumen: La fasceítis necrotizante es una infección que afecta tejidos blandos, producida por estreptococos beta hemolíticos grupo A. Su diagnóstico temprano es difícil, siendo más fácil conforme avanza el curso de la enfermedad. Para determinar si existía una relación entre los anti-inflamatorios no esteroideos y la aparición de fasceítis necrotizante, fue analizada la literatura médica de estudios clínicos en los últimos 41 años (base de datos de MEDLINE), los cuales evidenciaron que el tamaño de las muestras era pequeño, no eran randomizadas, no tenían grupos control y no lograron demostrar evidencia científica de causa-efecto entre los anti-inflamatorios no esteroideos y la fasceítis necrotizante, sin importar las vías de administración utilizadas. Con el fin de determinar si existe una asociación entre los anti-inflamatorios no esteroideos y fasceítis necrotizante, deben llevarse a cabo en el futuro estudios clínicos bien diseñados.

 

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Bisno A, Stevens D. Streptococcal infections of skin and soft tissues. NEngl J Med 1996; 334:240.

Guy C. Fulminating necrotizing fasciitis after intramuscular injectionof a corticoid. Contributing role of non-steroidal anti-inflammatoryagents. Therapie. 1993; 48: 489-90.

Stevens DL, Tanner MH, Winship J, Swarts R; Ries KM, SchlievertPM, Kaplan E. Severe group A streptococcal infections associated witha toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med1989; 321:1-7.

Wilson CB. Necrotizing fasciitis. Am Surg 1952; 18:416.

Stevens DL. Could nonsteroidal anti-inflammatory drugs (NSAID) en -hance de progression of bacterial infections to toxic shock syndrome ?Clin Infect Dis 1995; 21: 977.

Brantigan CO, Senkowsky J. Group A beta hemolytic streptococcal ne-crotizing fasciitis. Wounds 1995; 7:62-8

Descamps V, Aitken J, Lee MG. Hippocrates on necrotising fasciitis.Lancet 1994; 344:556.

Kahn LH. Necrotizing soft tissue infections reported with nonsteroidalantiinflammatory drugs. Ann Pharmacother 1997; 31(9): 1034-9

Kotrappa KS, Bansal RS, Amin NM. Necrotizing Fasciitis. Am FamPhysician 1996; 53:1691-7.

Chapnick EL, Abter EI. Infectious Disease Emergencies— Necrotizingsoft tissue infections. Infect Dis Clin North Am 1996; 10(4): 835-55.

Bergdoll MS, Chesney PJ. Toxic Shock Syndrome. Boca Raton, FL,CRC Press, 1991.

Morantes M, Lipsky BA. “ Flesh eating bacteria”: return of an old ne-mesis. Int J Dematol 1995; 34:461-3.

Katz AR, Morens DM. Severe streptococcal infections in historicalperspective. Clin Infect Dis 1992; 14:298-307.

Hoge CW, Schwartz B, Talkington DF, Breiman RF, MacNeill EM, En-glender SJ. The changing epidemiology of invasive group A streptococ-cal infections and the emergence of streptococcal toxic shock-like syn-drome: a retrospective population-based study. JAMA 1993; 269:384-389.

Davies HD, McGeer A, Schwartz B, Green K, Cann D, Simor AE, LowDE. Invasive group A streptococcal infections in Ontario, Canada. NEngl J Med 1996;335:547-554.

Centers for Disease Control and Prevention. Group A beta-hemolyticstreptococcal bacteremia: Colorado, 1989. MMWR 1990;39:3-6.

O’ Brien KL, Levine OS, Schwartz B. The changing epidemiology ofgroup Astreptococcus infections. Semin Pediatr Infect Dis. 1997; 8:1-8.

Davies HD, Matlow A, Scriver SR, Lovgren M, Talbot JA, Low DE.Apparent lower rates of streptococcal toxic shock syndrome and lowermortality in children with invasive group A streptococcal infectionscompared with adults. Pediatr Infect Dis J 1994;13:49-56.

Kaplan EL. Recent epidemiology of group A streptococcal infections inNorth America and abroad: an overview. Pediatrics 1996; 97(6 Pt 2):945-8

Cockerill FR, MacDonald KL, Thompson RL, Roberson F, Kohner PC,Besser-Wiek J, et al. An outbreak of invasive group A streptococcal di-sease associated with high carriage rates of the invasive clone amongschool-aged children. JAMA1997; 277:38-43.

Wolf JE, Rabinowitz LG. Streptococcal toxic shock-like syndrome.Arch Dermatol 1995;131:73-7.

Bronze MS, Dale JB. The reemergence of serious group A streptococ-cal infections and acute rheumatic fever. Am J Med Sci 1996; 311:41-54.

Stevens DL, Tanner MH, Winship J, Swarts R, Ries KM, SchlievertPM, et al. Severe group A streptococcal infections associated with a to-xic shock-like syndrome and scarlet fever toxin A. N Engl J Med 1989;321:1-7.

Schwartz B, Facklam RR, Breiman RF. Changing epidemiology ofgroup A streptococcal infection in the USA. Lancet 1990;336:1167-71.

White J, Herman A, Pullen AM, Kubo R, Kappler JW, Marrack P. T h eVbeta-specific superantigen staphylococcal enterotoxin B: stimulation ofmature Tcells and clonal deletion in neonatal mice. Cell 1989;56:27-35.

Leung DYM, Travers JB, Norris DA. The role of superantigens in skindisease. J Invest Dermatol 1995;105(Suppl):37s-42s.

Rosen H. Superantigens. Int J Dermatol 1997;36:14-6. Schlievert PM.Role of superantigens in human disease. J Infect Dis 1993;167:997-1002.

Shimozato T, Iwata M, Tamura N. Suppression of tumor necrosis fac-tor alpha production by a human immunoglobulin preparation for intra-venous use. Infect Immun 1990; 58:1384.

Stevens DL, Bryant AE, Hackett SP, Chang A, Peer G, Kosanke S,Emerson T, Hinshaw L. Group A streptococcal bacteremia: The role oftumor necrosis factor in shock and organ failure. J Infect Dis 1995;173:619-626.

Solomon L. Activation of latent infection by indomethacin: a report ofthree cases. Br. Med. J 1996; 1:961-62.

Solberg CO, Alfred CD, Hill HR. Influence of phenylbutazone on leu-kocyte chemiluminescence and function. Acta Pathol Microbiol Immu-nol Scand [C] 1978; 86:165-71

Brun-Buisson CJ, Saada M, Trunet P, Rapin M, Roujeau JC, Revuz J.Haemolytic streptococcal gangrene and non-steroidal-anti-inflamma-tory drugs. Br Med J 1985; 290:1786.

Krige JE, Spence RA, Potter PC, Terblanche J. Necrotizing Fasciitis af-ter diflunisal for minor injury. Lancet 1985; 2: 1432-1433.

Espersen GT, Larsen K. NSAID and fasciitis necroticans. Ugeskr Lae-ger 1987; 145:3475-3477.

Rimailho A, Riou B, Richard C, Auzepy P. Fulminant necrotizing fas-ciitis and non-steroidal-antiinflammatory drugs. J Infect Dis 1987;155:143-147.

Smith RJ, Berk SL. Necrotizing fasciitis and Nonsteroidal Anti-inflam-matory Drugs. South Med J. 1991; 84: 785-787.

Chaplain A. Acute cervical necrotizing fasciitis of pharyngeal origin:possible role of steroidal and non-steroidal anti-inflammatory agents.Apropos of 5 cases. Rev Laryngol Otol Rhinol (Bord) 1996; 117(5):377-80.

Zerr DM, Alexander ER, Duchin JS, Koutsky LA, Rubens CE. A case-control study of necrotizing fasciitis during primary varicella. Pedia-trics 1999; 103:783-90.

Kahn LH. Necrotizing soft tissue infections reported with non-steroidalantiinflammatory drugs. Ann Pharmacother 1997; Sep; 31(9): 1034-9.

Severe Invasive Group A Streptococcal Infections: A Subject Review(RE9804) American Academy of Pediatrics Committee on InfectiousDiseases, 1999.

Green RJ, Dafoe DC, Raffin TA. Necrotizing Fasciitis. Chest 1996; 110(1): 1.

Canadian Bacterial Surveillance Network, December 1999.

Stone DR, Gorbach SL. Necrotizing fasciitis. The changing spectrum. Dermatol Clin 1997; 15(2): 213-20.

Descargas

Publicado

2002-01-01

Cómo citar

Behm López, B., & Salas Herrera, I. (2002). El papel de los anti-inflamatorios no esteroideos en la producción de fasceítis necrotizante. Acta Médica Costarricense, 44(1), 5–9. https://doi.org/10.51481/amc.v44i1.392

Artículos más leídos del mismo autor/a